Risk-reducing medication for primary breast cancer: a network meta-analysis

To assess the efficacy and acceptability of single agent CPAs for the prevention of primary breast cancer, in unaffected women, at an above average risk of developing breast cancer.

Using a network meta-analysis, we also intend to rank single CPAs, based on their efficacy and acceptability (an endpoint that is defined as the inverse of CPA-related toxicity).

This is a protocol.

Share/Save
Health topics: